These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

643 related articles for article (PubMed ID: 27375017)

  • 61. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
    Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
    Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacological targeting of P300/CBP reveals EWS::FLI1-mediated senescence evasion in Ewing sarcoma.
    Wei E; Mitanoska A; O'Brien Q; Porter K; Molina M; Ahsan H; Jung U; Mills L; Kyba M; Bosnakovski D
    Mol Cancer; 2024 Oct; 23(1):222. PubMed ID: 39367409
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
    Balestra T; Manara MC; Laginestra MA; Pasello M; De Feo A; Bassi C; Guerzoni C; Landuzzi L; Lollini PL; Donati DM; Negrini M; Magnani M; Scotlandi K
    Mol Cancer Ther; 2022 Jan; 21(1):58-69. PubMed ID: 34667115
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
    Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
    Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.
    Selvanathan SP; Graham GT; Erkizan HV; Dirksen U; Natarajan TG; Dakic A; Yu S; Liu X; Paulsen MT; Ljungman ME; Wu CH; Lawlor ER; Üren A; Toretsky JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1307-16. PubMed ID: 25737553
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of siRNA nanocapsules targeted against the EWS-Fli1 oncogene in Ewing sarcoma.
    Toub N; Bertrand JR; Tamaddon A; Elhamess H; Hillaireau H; Maksimenko A; Maccario J; Malvy C; Fattal E; Couvreur P
    Pharm Res; 2006 May; 23(5):892-900. PubMed ID: 16715379
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 69. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
    Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
    Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
    [TBL] [Abstract][Full Text] [Related]  

  • 70. EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.
    He S; Huang Q; Hu J; Li L; Xiao Y; Yu H; Han Z; Wang T; Zhou W; Wei H; Xiao J
    Br J Cancer; 2019 Nov; 121(11):922-933. PubMed ID: 31649319
    [TBL] [Abstract][Full Text] [Related]  

  • 71. RETRACTED: Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage.
    Lee HJ; Yoon C; Schmidt B; Park DJ; Zhang AY; Erkizan HV; Toretsky JA; Kirsch DG; Yoon SS
    Mol Cancer Ther; 2013 Nov; 12(11):2591-600. PubMed ID: 23966622
    [TBL] [Abstract][Full Text] [Related]  

  • 72. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
    Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
    PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
    [TBL] [Abstract][Full Text] [Related]  

  • 73. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A; Tirode F; Cohen P; Delattre O
    Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.
    Hong SH; Youbi SE; Hong SP; Kallakury B; Monroe P; Erkizan HV; Barber-Rotenberg JS; Houghton P; Üren A; Toretsky JA
    Oncotarget; 2014 Jan; 5(2):338-50. PubMed ID: 24481407
    [TBL] [Abstract][Full Text] [Related]  

  • 75. ERG transcription factors have a splicing regulatory function involving RBFOX2 that is altered in the EWS-FLI1 oncogenic fusion.
    Saulnier O; Guedri-Idjouadiene K; Aynaud MM; Chakraborty A; Bruyr J; Pineau J; O'Grady T; Mirabeau O; Grossetête S; Galvan B; Claes M; Al Oula Hassoun Z; Sadacca B; Laud K; Zaïdi S; Surdez D; Baulande S; Rambout X; Tirode F; Dutertre M; Delattre O; Dequiedt F
    Nucleic Acids Res; 2021 May; 49(9):5038-5056. PubMed ID: 34009296
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
    Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
    Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
    [TBL] [Abstract][Full Text] [Related]  

  • 77. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.
    Riggi N; Knoechel B; Gillespie SM; Rheinbay E; Boulay G; Suvà ML; Rossetti NE; Boonseng WE; Oksuz O; Cook EB; Formey A; Patel A; Gymrek M; Thapar V; Deshpande V; Ting DT; Hornicek FJ; Nielsen GP; Stamenkovic I; Aryee MJ; Bernstein BE; Rivera MN
    Cancer Cell; 2014 Nov; 26(5):668-681. PubMed ID: 25453903
    [TBL] [Abstract][Full Text] [Related]  

  • 78. EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma.
    Katschnig AM; Kauer MO; Schwentner R; Tomazou EM; Mutz CN; Linder M; Sibilia M; Alonso J; Aryee DNT; Kovar H
    Oncogene; 2017 Oct; 36(43):5995-6005. PubMed ID: 28671673
    [TBL] [Abstract][Full Text] [Related]  

  • 79. ETS1, a Target Gene of the EWSR1::FLI1 Fusion Oncoprotein, Regulates the Expression of the Focal Adhesion Protein TENSIN3.
    Ebegboni VJ; Jones TL; Brownmiller T; Zhao PX; Pehrsson EC; Sundara Rajan S; Caplen NJ
    Mol Cancer Res; 2024 Jul; 22(7):625-641. PubMed ID: 38588446
    [TBL] [Abstract][Full Text] [Related]  

  • 80. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
    Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
    Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.